Literature DB >> 26916006

HSP90 and Immune Modulation in Cancer.

Michael W Graner1.   

Abstract

Heat-shock protein 90 (HSP90) is a highly conserved molecular chaperone that plays prominent functional roles in nearly all aspects of cell biology. As a chaperone, it interacts with literally hundreds of "clients," many of which are important drivers, regulators, and promoters of cancer. Thus, HSP90 is a high-value target in the development of anticancer therapeutics. Despite its popularity, our overall knowledge of HSP90 in immune function has lagged behind its well-recognized tumor-supportive roles. The use of inhibitors of HSP90 as chemical biological probes has been invaluable in revealing important roles for the chaperone in multiple aspects of immune function. Given this critical link, we must now consider the question of how immune outcomes may be affected by the HSP90 inhibitors currently in clinical development for the treatment of cancer. This chapter will review some of the immunological aspects of HSP90 function in terms of its intracellular and extracellular roles in antigen presentation, immune effector cell tasks, and regulation of inflammatory processes. This review will further examine the value of HSP90 inhibitors within the context of cancer immunotherapy and will discuss how these drugs might be optimally utilized in combination with immune stimulatory approaches against cancer.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen presentation; HSP90; Immunotherapy; Inflammation; Inhibitor; Tumor immunity

Mesh:

Substances:

Year:  2015        PMID: 26916006     DOI: 10.1016/bs.acr.2015.10.001

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  23 in total

1.  Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts.

Authors:  Ranjit K Mehta; Sanjima Pal; Koushik Kondapi; Merna Sitto; Cuyler Dewar; Theresa Devasia; Matthew J Schipper; Dafydd G Thomas; Venkatesha Basrur; Manjunath P Pai; Yoshihiro Morishima; Yoichi Osawa; William B Pratt; Theodore S Lawrence; Mukesh K Nyati
Journal:  Clin Cancer Res       Date:  2020-07-27       Impact factor: 12.531

Review 2.  A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond.

Authors:  Tony Taldone; Tai Wang; Anna Rodina; Naga Vara Kishore Pillarsetty; Chander S Digwal; Sahil Sharma; Pengrong Yan; Suhasini Joshi; Piyusha P Pagare; Alexander Bolaender; Gail J Roboz; Monica L Guzman; Gabriela Chiosis
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-04-01       Impact factor: 10.005

Review 3.  Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development.

Authors:  Len Neckers; Brian Blagg; Timothy Haystead; Jane B Trepel; Luke Whitesell; Didier Picard
Journal:  Cell Stress Chaperones       Date:  2018-02-01       Impact factor: 3.667

4.  Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.

Authors:  Alex M Jaeger; Lauren Stopfer; Sunmin Lee; Giorgio Gaglia; Demi Sandel; Sandro Santagata; Nancy U Lin; Jane B Trepel; Forest White; Tyler Jacks; Susan Lindquist; Luke Whitesell
Journal:  Clin Cancer Res       Date:  2019-06-18       Impact factor: 12.531

5.  Aha1 Is an Autonomous Chaperone for SULT1A1.

Authors:  Xiaochuan Liu; Yinsheng Wang
Journal:  Chem Res Toxicol       Date:  2022-08-04       Impact factor: 3.973

6.  Glioblastoma Extracellular Vesicle-Specific Peptides Inhibit EV-Induced Neuronal Cytotoxicity.

Authors:  Wenbo Zhou; Julia Craft; Alex Ojemann; Luke Bergen; Arin Graner; Aitana Gonzales; Qianbin He; Timothy Kopper; Marie Smith; Michael W Graner; Xiaoli Yu
Journal:  Int J Mol Sci       Date:  2022-06-28       Impact factor: 6.208

7.  Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.

Authors:  Sarwat Naz; Andrew J Leiker; Rajani Choudhuri; Olivia Preston; Anastasia L Sowers; Sangeeta Gohain; Janet Gamson; Askale Mathias; Carter Van Waes; John A Cook; James B Mitchell
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-04-07       Impact factor: 8.013

8.  Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer.

Authors:  Yuchen Zhang; Michael B Ware; Mohammad Y Zaidi; Amanda N Ruggieri; Brian M Olson; Hannah Komar; Matthew R Farren; Ganji Purnachandra Nagaraju; Chao Zhang; Zhengjia Chen; Juan M Sarmiento; Rafi Ahmed; Shishir K Maithel; Bassel F El-Rayes; Gregory B Lesinski
Journal:  Mol Cancer Ther       Date:  2020-10-09       Impact factor: 6.009

9.  Exploiting heat shock protein expression to develop a non-invasive diagnostic tool for breast cancer.

Authors:  Brian T Crouch; Jennifer Gallagher; Roujia Wang; Joy Duer; Allison Hall; Mary Scott Soo; Philip Hughes; Timothy Haystead; Nirmala Ramanujam
Journal:  Sci Rep       Date:  2019-03-05       Impact factor: 4.379

Review 10.  Heat Shock Proteins as Immunomodulants.

Authors:  Tawanda Zininga; Lebogang Ramatsui; Addmore Shonhai
Journal:  Molecules       Date:  2018-11-01       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.